[{"id":"ae21f239-5ecf-43a4-82a8-5216e3c17404","acronym":"","url":"https://clinicaltrials.gov/study/NCT02297698","created_at":"2021-01-18T10:50:01.049Z","updated_at":"2024-07-02T16:35:26.527Z","phase":"Phase 2","brief_title":"Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients","source_id_and_acronym":"NCT02297698","lead_sponsor":"Cancer Insight, LLC","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HLA-A*24","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Leukine (sargramostim) • NeuVax (nelipepimut-S)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2023-12-12"},{"id":"e6f354cb-5f37-4b5a-98f8-92dbfe40f474","acronym":"","url":"https://clinicaltrials.gov/study/NCT01570036","created_at":"2021-01-18T06:39:44.210Z","updated_at":"2024-07-02T16:36:37.945Z","phase":"Phase 2","brief_title":"Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax","source_id_and_acronym":"NCT01570036","lead_sponsor":"George E. Peoples","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Leukine (sargramostim) • NeuVax (nelipepimut-S)"],"overall_status":"Completed","enrollment":" Enrollment 275","initiation":"Initiation: 05/21/2013","start_date":" 05/21/2013","primary_txt":" Primary completion: 09/28/2018","primary_completion_date":" 09/28/2018","study_txt":" Completion: 09/28/2018","study_completion_date":" 09/28/2018","last_update_posted":"2020-12-02"},{"id":"8e71adec-d6e4-47ac-991d-bcc2a2e03ee7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00841399","created_at":"2021-01-18T03:12:10.541Z","updated_at":"2024-07-02T16:36:47.084Z","phase":"Phase 1","brief_title":"Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients","source_id_and_acronym":"NCT00841399","lead_sponsor":"COL George Peoples, MD, FACS","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NeuVax (nelipepimut-S)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 07/01/2001","start_date":" 07/01/2001","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 03/01/2013","study_completion_date":" 03/01/2013","last_update_posted":"2020-03-31"},{"id":"14154bf1-d1dc-4c07-87fe-c88f364fa07d","acronym":"PRESENT","url":"https://clinicaltrials.gov/study/NCT01479244","created_at":"2021-01-18T06:10:28.956Z","updated_at":"2024-07-02T16:37:24.991Z","phase":"Phase 3","brief_title":"Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence","source_id_and_acronym":"NCT01479244 - PRESENT","lead_sponsor":"Galena Biopharma, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukine (sargramostim) • NeuVax (nelipepimut-S)"],"overall_status":"Completed","enrollment":" Enrollment 758","initiation":"Initiation: 11/01/2011","start_date":" 11/01/2011","primary_txt":" Primary completion: 09/21/2016","primary_completion_date":" 09/21/2016","study_txt":" Completion: 09/21/2016","study_completion_date":" 09/21/2016","last_update_posted":"2017-02-27"}]